Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Biotechnology

Concord Biotech Limited, a biopharma company, engages in the research and development, manufacturing, marketing, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, and pimecrolimus for immunosuppressants therapeutic segment; temsirolimus, everolimus, romidepsin, mitomycin, midostaurin, dactinomycin, staurosporin, mitoguazone, and everolimus premix for oncology therapeutic segment; mupirocin, mupirocin calcium, polymyxin B sulfate, fidaxomicin, vancomycin hydrochloride, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi, micafungin sodium, amphotericin B, and nystatin for anti-fungal therapeutic segment; and lovastatin, pravastatin sodium, and enzymes for other applications. In addition, it provides contract research and manufacturing services in the areas of fermentation and semi-synthesis products. Concord Biotech Limited was incorporated in 1984 and is based in Ahmedabad, India.

Revenue projections:

Revenue projections for CONCORDBIO
Revenue projections for CONCORDBIO

Revenues for CONCORDBIO are forecasted to decline from last year's levels, prompting caution among investors. When revenues fall, it can have a significant negative impact on the company's bottom line, reducing profitability and making the stock less attractive to risk-averse investors.

Financial Ratios:

currentRatio 0.00000
forwardPE 38.31029
debtToEquity 0.21500
earningsGrowth -0.02000
revenueGrowth 0.01400
grossMargins 0.73897
operatingMargins 0.34677
trailingEps 31.20000
forwardEps 0.00000

CONCORDBIO's low earnings and revenue growth suggest shrinking profits. This negative trend could indicate that the company is struggling to maintain its financial performance and may face challenges ahead.
CONCORDBIO's positive gross and operating margins suggest that the company is operating profitably. These strong margins indicate effective cost management and revenue generation, contributing to a solid financial foundation.

Price projections:

Price projections for CONCORDBIO
Price projections for CONCORDBIO

The price of CONCORDBIO has regularly been close to the lower end of projections, suggesting that it might be struggling to meet market expectations. This trend raises questions about the company's future performance.

Insider Transactions:

Insider Transactions for CONCORDBIO
Insider Transactions for CONCORDBIO


2 CONCORDBIO shares were sold in recent transactions, with market price at 1583.050048828125.There were no sell transactions during the given period.The higher number of buys versus sells near CONCORDBIO's current price suggests optimism among investors. This buying trend could be interpreted as a sign that the market expects favorable outcomes for the stock in the near future.

Recommendation changes over time:

Recommendations trend for CONCORDBIO
Recommendations trend for CONCORDBIO


CONCORDBIO has recently received a buy bias from analysts, indicating that the stock is being perceived as a favorable investment. This positive sentiment could encourage investors to see CONCORDBIO as a wise place to allocate their funds, potentially leading to increased interest in the company's stock.